Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Top Cited Papers
- 17 June 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Chemical Biology
- Vol. 15 (7), 737-746
- https://doi.org/10.1038/s41589-019-0279-5
Abstract
Ligand-dependent protein degradation has emerged as a compelling strategy to pharmacologically control the protein content of cells. So far, however, only a limited number of E3 ligases have been found to support this process. Here, we use a chemical proteomic strategy that leverages broadly reactive, cysteine-directed electrophilic fragments coupled to selective ligands for intracellular proteins (for example, SLF for FKBP12, JQ1 for BRD4) to screen for heterobifunctional degrader compounds (or proteolysis targeting chimeras, PROTACs) that operate by covalent adduction of E3 ligases. This approach identified DCAF16—a poorly characterized substrate recognition component of CUL4-DDB1 E3 ubiquitin ligases—as a target of electrophilic PROTACs that promote the nuclear-restricted degradation of proteins. We find that only a modest fraction (~10–40%) of DCAF16 needs to be modified to support protein degradation, pointing to the potential for electrophilic PROTACs to induce neosubstrate degradation without substantially perturbing the function of the participating E3 ligase.Keywords
This publication has 51 references indexed in Scilit:
- Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degradersEssays in Biochemistry, 2017
- Protein degradation: a validated therapeutic strategy with exciting prospectsEssays in Biochemistry, 2017
- Targeted Protein Degradation: from Chemical Biology to Drug DiscoveryCell Chemical Biology, 2017
- Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathwayBiochemical Journal, 2017
- Targeted Protein Degradation by Small MoleculesAnnual Review of Pharmacology and Toxicology, 2017
- Cereblon and its downstream substrates as molecular targets of immunomodulatory drugsInternational Journal of Hematology, 2016
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligaseNature, 2016
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsScience, 2014
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Identification of a Primary Target of Thalidomide TeratogenicityScience, 2010